ATB-346 is a non-steroidal anti-inflammatory drug (NSAID) that releases hydrogen sulfide (H2S) and a derivative of naproxen . It inhibits the proliferation of, and induces apoptosis in, A375 melanoma cells when used at a concentration of 100 μM. ATB-346 decreases prostaglandin E2 (PGE2) production in inflammatory exudates, reduces paw edema, and increases plasma levels of sulfide in a mouse model of zymosan-induced arthritis. It reduces the size of acetic acid-induced gastric ulcers in mice when administered at a dose of 60 μmol/kg. ATB-346 (30 μmol/kg) improves motor function in a mouse model of spinal cord injury.
[1] wallace j l, caliendo g, santagada v, et al. markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (atb-346). british journal of pharmacology, 2010, 159(6): 1236-1246.
